Stem Cell Innovations Produces Human Pluripotent Stem Cells; Cells Eligible for Use In Government Funded Laboratories

SCOTCH PLAINS, N.J.--(BUSINESS WIRE)--March 29, 2006--Dr. James H. Kelly, Chief Executive Officer of Stem Cell Innovations, Inc. (OTCBB: SCLL), will present data today at the Keystone Symposium on Stem Cells in Vancouver demonstrating that the Company has produced multiple lines of human pluripotent stem cells. Because these cells are derived from fetal tissue, not early embryos, they are eligible for use in laboratories funded by the National Institutes of Health.